drugset
drugset / Trial / NCT02172755

Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites

NCT02172755 ↗

Phase 1 Completed 30 enrolled Bial - Portela C S.A.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effects of age on the pharmacokinetic profile of BIA 2-093 and its active metabolites.

Timeline

Start
2002-06
Primary completion
2002-08
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 600 mg —

Indications

epilepsy